Fresenius Medical Care (ETR:FME) Share Price Passes Above 200 Day Moving Average - Time to Sell?

Key Points

• Fresenius Medical Care AG shares have crossed above their 200-day moving average, indicating positive momentum in the stock, which currently trades at €47.00 ($54.65).
• The company has a market capitalization of $13.61 billion and reported a P/E ratio of 20.66, suggesting relatively healthy valuations.
• Fresenius Medical Care provides specialized dialysis and related services for individuals with renal diseases globally, including outpatient clinics and hospital-based dialysis services.

Fresenius Medical Care AG (ETR:FME - ) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of €45.71 ($53.15) and traded as high as €47.86 ($55.65). Fresenius Medical Care shares last traded at €47.00 ($54.65), with a volume of 395,337 shares trading hands.

Fresenius Medical Care Stock Performance

The company has a market cap of $13.61 billion, a P/E ratio of 20.66, a PEG ratio of 0.42 and a beta of 0.86. The firm has a 50 day moving average of €43.51 and a 200-day moving average of €45.71. The company has a quick ratio of 0.80, a current ratio of 1.37 and a debt-to-equity ratio of 82.24.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.